<DOC>
	<DOCNO>NCT02384967</DOCNO>
	<brief_summary>Phase II trial assess efficacy reduce dose strategy darunavir 400 mg/d HIV-1 infect patient virologically suppress daily regimen include darunavir 800 mg/d two nucleoside reverse transcriptase inhibitor ( NRTI ) , maintain viral load lower 50 copy / mL 48 week treatment .</brief_summary>
	<brief_title>Evaluation Dose Reduction Darunavir ( 400 mg/d ) Virologically Suppressed HIV-1 Patients</brief_title>
	<detailed_description>Principal objective : To evaluate proportion subject virologically suppress week 48 ( viral load=VL ≤ 50 cp/mL ) tri-therapy contain darunavir dose 400 mg/d . Secondary objective : To evaluate baseline week 48 : proportion subject : virological failure ( confirm VL &gt; 50 cp/mL ) confirm 2nd measure make 2 4 week , VL ≤ 50 cp/mL 20 50 cp/mL , emerge drug resistance virological failure , CD4 cell count evolution , HIV DNA evolution , morphological glucido-lipid parameter modification , digestive treatment tolerance , adherence treatment , overall cost antiretroviral therapy , factor associate virological failure include baseline nadir CD4 cell count , darunavir plasma level , baseline HIV DNA viral load .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>HIV1 infect adult , age ≥ 18 year , onceaday ritonavirboosted darunavir 800mg/j contain regimen plus 2 NRTI ( ≥ 6 month ) , virologically control ( VL ≤ 50 cp/ml , ≥ 1 year , least 2 VL space least 3 month apart last 12 month ) CD4 count ≥ 300/mm3 ≥ 6 month , virus sensible darunavir use NRTI ( pretreatment resistance genotypic test available ) history virological failure ( VL &gt; 200 cp/mL ≥ 6 month PI and/or use NRTI ) , current opportunistic infection , renal clearance ≥ 60 mL/min tenofovir use , transaminase ( SGOT , SGPT ) plasma level &lt; 2N , hemoglobin &gt; 11 g/dL , platelet count &gt; 150 000/mm3 , negative pregnancy test woman childbearing potential , informed write consent sign investigator subject , national insurance scheme ( article L112111 French Public Health code ) , participation clinical trial HIV2 infection , current antiretroviral therapy different onceaday ritonavirboosted darunavir 800mg/j contain regimen plus 2 NRTI , virus genotypically resistant darunavir use NRTIs , history virological failure ( VL &gt; 200 cp/mL ≥ 6 month PI and/or use NRTI ) , irregular followup and/or history lack adherence ART ≤ 12 month , current pregnancy , current opportunistic infection , associate treatment contain one drug interact hepatic cytochrome , addictive behavior ( alcohol consumption , drug … ) likely jeopardize safety treatment / patient compliance adherence trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>